Old Web
English
Sign In
Acemap
>
authorDetail
>
Surapol Issaragrilsil
Surapol Issaragrilsil
Medicine
Nilotinib
Immunology
Imatinib
Chronic phase CML
3
Papers
57
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
A Retrospective Study on Safety, Efficacy and Cost of the Chemo-Mobilization for Patients Planned to Undergo Autologous Hematopoietic Stem Cell Transplant: The Secom Study
2014
Blood
Surapol Issaragrilsil
Yeow-Tee Yt Goh
Anskar Y. H. Leung
S Fadilah S. Abdul Wahid
Hwai Tzeng Cheng
Show All
Source
Cite
Save
Citations (0)
Efficacy and Safety of Nilotinib (NIL) vs Imatinib (IM) in Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Long-Term Follow-Up (f/u) of ENESTnd
2014
Blood
Richard A. Larson
Dong-Wook Kim
Surapol Issaragrilsil
Philipp le Coutre
Pedro Enrique Dorlhiac-Llacer
Gabriel Etienne
Richard E. Clark
Ian W. Flinn
Hirohisa Nakamae
Andreas Hochhaus
Giuseppe Saglio
Hagop M. Kantarjian
Breanne Donohue
Weiping Deng
Hans D. Menssen
Timothy P. Hughes
Show All
Source
Cite
Save
Citations (49)
Impact of early molecular response to nilotinib (NIL) or imatinib (IM) on the long-term outcomes of newly diagnosed patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): Landmark analysis of 4-year (y) data from ENESTnd.
2013
Journal of Clinical Oncology
Giuseppe Saglio
Timothy P. Hughes
Richard A. Larson
Surapol Issaragrilsil
Turkina Ag
Juan Luis Steegmann
Jose Luis Lopez
Chiaki Nakaseko
Matt Kalaycio
Françoise Huguet
Charisse Kemp
Xiaolin Fan
Hans D. Menssen
Hagop M. Kantarjian
Andreas Hochhaus
Show All
Source
Cite
Save
Citations (8)
1